Poop pills plus immunotherapy: a new hope for melanoma that never came
NCT ID NCT06030037
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 27 times
Summary
This study aimed to see if adding a healthy donor fecal transplant (hdFMT) to standard immunotherapy (pembrolizumab/lenvatinib) could help people with advanced melanoma that stopped responding to treatment. The plan was to enroll about 0 participants and follow them for 104 weeks. However, the study was withdrawn before any patients were treated, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PD-1 REFRACTORY ADVANCED MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.